Apaporis

Apaporis is a biotechnology company headquartered in St. Louis, Missouri, specializing in the discovery and development of next-generation antibiotics. The company's primary focus is addressing the critical global health challenge of multi-drug resistant (MDR) Gram-negative bacterial infections. Apaporis utilizes a proprietary platform to identify novel small molecule candidates that target unique pathways in pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii. Founded by Dr. Michael Kinch, the company is supported by regional venture investors like BioGenerator. Apaporis aims to advance its lead candidates through preclinical development to provide much-needed solutions for hospital-acquired infections.